NIKKEI 225
28,039.87 +256.94 (+0.92%) HANG SENG
20,451.13 +142.00 (+0.70%) CRUDE OIL
74.30 -0.07 (-0.09%) GOLD FUTURES
1,996.80 -0.90 (-0.05%) DOW
32,859.03 +141.43 (+0.43%) Bitcoin GBP
22,698.56 -378.18 (-1.64%)
GlaxoSmithKline plc (GLAXF)
| Previous close | 17.55 |
| Open | 17.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 17.20 - 17.20 |
| 52-week range | 13.48 - 23.40 |
| Volume | |
| Avg. volume | 2,088 |
| Market cap | 71.723B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 12.74 |
| EPS (TTM) | 1.35 |
| Earnings date | N/A |
| Forward dividend & yield | 0.73 (4.24%) |
| Ex-dividend date | 23 Feb 2023 |
| 1y target est | N/A |
- Reuters
Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSK
The Biden Administration told the U.S. Supreme Court on Wednesday that it should agree to hear a patent appeal over drug labels involving Teva Pharmaceuticals USA Inc and GlaxoSmithKline LLC that could have significant ramifications for the generic-drug industry. The U.S. Solicitor General said Teva's generic version of GSK's heart drug Coreg could not have violated GSK's patent rights because Teva omitted the infringing use of the drug from its labeling. Such "skinny labels" typically allow generic drugmakers to launch their products earlier while avoiding liability for infringing brand-name drugmakers' patents.
- Reuters
GSK sees $500 million peak sales for yeast infection pill licensed from Scynexis
LONDON (Reuters) -British drugmaker GSK sees peak sales of more than $500 million for a drug to treat yeast infections that it licensed from U.S. biotech company Scynexis in a $90 million deal announced on Wednesday, a top GSK executive said. The pill, Brexafemme, made just $1.6 million in revenues in the third quarter of last year, according to the most recent financial results from Scynexis, which specialises in anti-fungal treatments. But GSK's Chief Commercial Officer Luke Miels told journalists he was confident that, as a big pharma company with experience building awareness among doctors and patients, GSK could change the trajectory of the product over time.
- Reuters
GSK licenses companies to make cheap copies of HIV prevention drug
LONDON (Reuters) -British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new cases occur. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, which aims to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent.
